Shanghai Pharmaceuticals Holding Co., Ltd

SZSC:2607 Stock Report

Market Cap: HK$67.2b

Shanghai Pharmaceuticals Holding Management

Management criteria checks 3/4

Shanghai Pharmaceuticals Holding's CEO is Bo Shen, appointed in Jun 2023, has a tenure of 2.42 years. total yearly compensation is CN¥3.05M, comprised of 53.3% salary and 46.7% bonuses, including company stock and options. directly owns 0.002% of the company’s shares, worth HK$1.30M. The average tenure of the management team and the board of directors is 2.4 years and 2.4 years respectively.

Key information

Bo Shen

Chief executive officer

CN¥3.1m

Total compensation

CEO salary percentage53.34%
CEO tenure2.4yrs
CEO ownership0.002%
Management average tenure2.4yrs
Board average tenure2.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bo Shen's remuneration changed compared to Shanghai Pharmaceuticals Holding's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

CN¥6b

Jun 30 2025n/an/a

CN¥6b

Mar 31 2025n/an/a

CN¥4b

Dec 31 2024CN¥3mCN¥2m

CN¥5b

Sep 30 2024n/an/a

CN¥4b

Jun 30 2024n/an/a

CN¥4b

Mar 31 2024n/an/a

CN¥4b

Dec 31 2023CN¥6mCN¥1m

CN¥4b

Sep 30 2023n/an/a

CN¥5b

Jun 30 2023n/an/a

CN¥5b

Mar 31 2023n/an/a

CN¥6b

Dec 31 2022CN¥6mCN¥1m

CN¥6b

Sep 30 2022n/an/a

CN¥5b

Jun 30 2022n/an/a

CN¥5b

Mar 31 2022n/an/a

CN¥4b

Dec 31 2021CN¥6mCN¥1m

CN¥5b

Sep 30 2021n/an/a

CN¥5b

Jun 30 2021n/an/a

CN¥6b

Mar 31 2021n/an/a

CN¥6b

Dec 31 2020CN¥5mCN¥1m

CN¥4b

Sep 30 2020n/an/a

CN¥4b

Jun 30 2020n/an/a

CN¥4b

Mar 31 2020n/an/a

CN¥4b

Dec 31 2019CN¥6mCN¥1m

CN¥4b

Sep 30 2019n/an/a

CN¥4b

Jun 30 2019n/an/a

CN¥4b

Mar 31 2019n/an/a

CN¥4b

Dec 31 2018CN¥3mCN¥800k

CN¥4b

Compensation vs Market: Bo's total compensation ($USD430.19K) is below average for companies of similar size in the Hong Kong market ($USD871.40K).

Compensation vs Earnings: Bo's compensation has been consistent with company performance over the past year.

CEO

Bo Shen (52 yo)

2.4yrs
Tenure
CN¥3,054,000
Compensation

Mr. Bo Shen had been the Chief Financial Officer of Shanghai Pharmaceuticals Holding Co., Ltd. since March 2010 and served as its Head of the Accounting Department. He serves as President of Shanghai Pharm...

Leadership Team

NamePositionTenureCompensationOwnership
Qiuhua Yang
Executive Chairman1.7yrsno datano data
Bo Shen
President & Executive Director2.4yrsCN¥3.05m0.0019%
HK$ 1.3m
Yongzhong Li
VP & Executive Directorno dataCN¥2.75mno data
Ming Dong
Executive Director2.4yrsno datano data
Tao Zhong
VP, Board Secretary & Joint Company Secretary3.3yrsCN¥2.04mno data
Shuai Shao
Vice President3.3yrsCN¥1.83mno data
Yadong Zhou
VP & CFOless than a yearno datano data
Shunjiang Yu
Chief Medical Officerno datano datano data
Pui Kiu Wong
Joint Company Secretary1.8yrsno datano data
Ying Ke
Director & General Manager of R&D Management Centerno datano datano data
Linqiong Dong
Securities Affairs Representativeno datano datano data
2.4yrs
Average Tenure
52.5yo
Average Age

Experienced Management: 2607's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Qiuhua Yang
Executive Chairman1.7yrsno datano data
Bo Shen
President & Executive Director12.4yrsCN¥3.05m0.0019%
HK$ 1.3m
Yongzhong Li
VP & Executive Director12.4yrsCN¥2.75mno data
Ming Dong
Executive Director2.4yrsno datano data
Wenxue Zhang
Non-Executive Director1.4yrsno datano data
Manson Fok
Independent Non-Executive Director6.4yrsCN¥300.00kno data
Youli Xu
Chief Supervisor9.4yrsno datano data
Zhaoyang Gu
Independent Non-Executive Director6.4yrsCN¥300.00kno data
Weidong Yu
Employee Representative Supervisor2.4yrsno datano data
Zhong Wang
Independent Non-Executive Director2.4yrsCN¥300.00kno data
Kwan Man
Independent Non-Executive Directorless than a yearno datano data
Jun Wan
Independent Directorless than a yearno datano data
2.4yrs
Average Tenure
55yo
Average Age

Experienced Board: 2607's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/15 15:05
End of Day Share Price 2025/11/14 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shanghai Pharmaceuticals Holding Co., Ltd is covered by 38 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Helena QiuCCB International Securities Limited
Harry HeCGS International